Company Overview
| Stock Name | Biodlink-B |
|---|---|
| Stock Code | 01875 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一間臨床階段生物製藥公司,致力於開發及商業化創新型腫瘤藥物及療法,擁有針對各類癌症的綜合性在研腫瘤藥物組合,包括單克隆抗體、抗體偶聯藥物、溶瘤病毒藥物及特種腫瘤藥物(如脂質體藥物),並建立了集發現、產程開發、質量管理、臨床前及臨床開發、商業規模生產基地和銷售及營銷能力於一體的綜合平台。 |
| Listing Date | 2019-11-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 蘇州市 蘇州工業園區 長陽街120號 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.totbiopharm.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 6.55 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-10-29 to 2019-11-01 |
| Global Offering Shares | 90,000,000 shares |
| HK Public Offer Shares (Initial) | 9,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 81,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 570,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 26.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 589,500,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 67 | HK$ 439 |
| 2 lots | 159 | HK$ 1,041 |
| 2 lots | 165 | HK$ 1,081 |
| 5 lots | 400 | HK$ 2,620 |
| 11 lots | 800 | HK$ 5,240 |
| 17 lots | 1,200 | HK$ 7,860 |
| 23 lots | 1,600 | HK$ 10,480 |
| 29 lots | 2,000 | HK$ 13,100 |
| 35 lots | 2,400 | HK$ 15,720 |
| 41 lots | 2,800 | HK$ 18,340 |
| 47 lots | 3,200 | HK$ 20,960 |
| 53 lots | 3,600 | HK$ 23,580 |
| 59 lots | 4,000 | HK$ 26,200 |
| 119 lots | 8,000 | HK$ 52,400 |
| 179 lots | 12,000 | HK$ 78,600 |
| 358 lots | 24,000 | HK$ 157,200 |
| 477 lots | 32,000 | HK$ 209,600 |
| 537 lots | 36,000 | HK$ 235,800 |
| 597 lots | 40,000 | HK$ 262,000 |
| 1,194 lots | 80,000 | HK$ 524,000 |
| 1,791 lots | 120,000 | HK$ 786,000 |
| 2,388 lots | 160,000 | HK$ 1,048,000 |
| 2,985 lots | 200,000 | HK$ 1,310,000 |
| 3,582 lots | 240,000 | HK$ 1,572,000 |
| 4,179 lots | 280,000 | HK$ 1,834,000 |
| 4,776 lots | 320,000 | HK$ 2,096,000 |
| 5,373 lots | 360,000 | HK$ 2,358,000 |
| 5,970 lots | 400,000 | HK$ 2,620,000 |
| 8,955 lots | 600,000 | HK$ 3,930,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 11,940 lots | 800,000 | HK$ 5,240,000 |
| 14,925 lots | 1,000,000 | HK$ 6,550,000 |
| 29,850 lots | 2,000,000 | HK$ 13,100,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.99B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +225% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,018,500,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣268.3百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 80,100,000 |
| Listing Expenses / Funds Raised | ~13.59% |
| Total Pre-IPO Investment | 186.0百萬美元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 |
|---|---|---|
| Revenue | 51,608 | 39,219 |
| Cost of sales | -4,242 | -5,980 |
| Other income and gains, net | 6,000 | 11,808 |
| Selling and distribution expenses | -28,886 | -38,935 |
| Administrative expenses | -24,514 | -54,638 |
| Operating profit | -105,969 | -237,177 |
| Net finance costs | 193 | -1,677 |
| Profit before tax | -148,687 | -268,263 |
| Income tax expense | 0 | 0 |
| Profit for the year | -148,687 | -268,263 |
| Profit attributable to owners | -148,687 | -268,263 |
Balance Sheet
| Item | 2017 | 2018 | 2019-04 |
|---|---|---|---|
| Cash and cash equivalents | 24,581 | 256,751 | |
| Trade and bills receivables | 6,500 | 9,694 | |
| Inventories | 980 | 3,105 | |
| Total current assets | 87,974 | 299,687 | |
| Total assets | 364,057 | 677,238 | |
| Total current liabilities | 21,787 | 75,139 | |
| Total liabilities | 286,741 | 861,716 | |
| Total equity | 77,316 | -184,478 | |
| Equity attributable to owners | 77,316 | -184,478 | |
| Interest-bearing borrowings | 30,000 | 500 | 0 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019-04 |
|---|---|---|---|
| Net cash from operating activities | -117,388 | -176,832 | |
| Net cash from investing activities | -110,957 | -47,067 | |
| Net cash from financing activities | 235,179 | 457,601 | |
| Net increase in cash | 6,834 | 233,702 | |
| Purchase of PP&E | -111,908 | -69,604 | -19,489 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 6.26 |
|---|---|
| First Day Open | HK$ 6.43 |
| First Day Change | -4.43% |
| First Day Volume | 26029200.0 |
| First Day Turnover | 165388000.0 |
| Use of Proceeds | 1、約30.0%(或153.5百萬港元)將為TAB008的進行中及計劃進行的臨床試驗、注冊備案準備及潛在商業推出(包括銷售及營銷)提供資金;
2、約50.0%(或255.7百萬港元)將為我們研發中的其他在研藥物的進行中及計劃進行的臨床前及臨床試驗、設施擴充、注冊備案準備及潛在商業推出(包括銷售及營銷)提供資金;
3、約15.0%,或76.7百萬港元將用于非項目指定的資本開支;
4、約2.0%(或10.2百萬港元)將為透過內部研究及外部許可以及業務開發合作,持續擴展癌癥及其他潛在治療領域的產品組合提供資金;
5、約3.0%(或15.3百萬港元)將用于我們的營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
Overall Coordinators (2)
Joint Bookrunners (4)
Joint Lead Managers (6)
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Yuanta Securities (Hong Kong) Company Limited CE ABS015
China Renaissance Securities (Hong Kong) Limited CE AZX839
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
LUK FOOK SECURITIES (HK) LIMITED CE ACU547
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Vivo Funds | 78,366,820 HKD | — | 13.29% | — | 6 months | 2020-05-08 |
| 2 | 年兴国际(维京群岛)有限公司 | 39,182,100 HKD | — | 6.65% | — | 6 months | 2020-05-08 |
| 3 | 晟德大药厂股份有限公司 | 39,182,100 HKD | — | 6.65% | — | 6 months | 2020-05-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 付山 | — |
| Company Secretary | 姚朝昶、呂穎一 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 晟德大藥廠(連同玉晟)為控股股東。緊隨全球發售完成後(假設超額配股權未獲行使),晟德大藥廠持股31.43%、玉晟持股0.85%;Vivo Capital Fund VIII, L.P.及Vivo Capital Surplus Fund VIII, L.P.合計持股17.97%;鈞信持股9.93%;Advantech Capital V持股8.62%。 |
|---|




